Theravance Biopharma, Inc. Quarterly Interest Expense in USD from Q1 2016 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of the cost of borrowed funds accounted for as interest expense.
Summary
Theravance Biopharma, Inc. quarterly/annual Interest Expense history and growth rate from Q1 2016 to Q1 2024.
  • Theravance Biopharma, Inc. Interest Expense for the quarter ending March 31, 2024 was $629K, a 14.4% increase year-over-year.
  • Theravance Biopharma, Inc. Interest Expense for the twelve months ending March 31, 2024 was $2.43M, a 49.2% decline year-over-year.
  • Theravance Biopharma, Inc. annual Interest Expense for 2023 was $2.35M, a 63.1% decline from 2022.
  • Theravance Biopharma, Inc. annual Interest Expense for 2022 was $6.37M, a 25.5% decline from 2021.
  • Theravance Biopharma, Inc. annual Interest Expense for 2021 was $8.55M, unchanged from 2020.
Interest Expense, Trailing 12 Months (USD)
Interest Expense, Quarterly (USD)
Interest Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $2.43M $629K +$79K +14.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $2.35M $623K +$73K +13.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-01
Q3 2023 $2.28M $609K -$936K -60.6% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $3.21M $568K -$1.57M -73.4% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-09
Q1 2023 $4.78M $550K -$1.59M -74.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $6.37M $550K +$17.6M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-01
Q3 2022 -$11.3M $1.55M -$591K -27.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$10.7M $2.14M -$9.48M -81.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 -$1.19M $2.14M -$9.74M -82% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $8.55M -$17.1M +$7.28M +29.9% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-01
Q3 2021 $1.26M $2.14M -$9.44M -81.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $10.7M $11.6M +$221K +1.94% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $10.5M $11.9M +$1.93M +19.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q4 2020 $8.55M -$24.4M -$32.4M -403% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-01
Q3 2020 $40.9M $11.6M +$3.51M +43.4% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 $37.4M $11.4M +$3.49M +44.2% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $33.9M $9.94M +$2.08M +26.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $31.9M $8.04M +$3.96M +97.4% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 $27.9M $8.07M +$5.93M +278% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $22M $7.9M +$5.76M +270% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $16.2M $7.86M +$5.72M +268% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q4 2018 $10.5M $4.07M +$1.93M +90.5% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-26
Q3 2018 $8.55M $2.14M +$1K +0.05% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 $8.55M $2.14M $0 0% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-05
Q1 2018 $8.55M $2.14M $0 0% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-10
Q4 2017 $8.55M $2.14M +$733K +52.2% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-27
Q3 2017 $7.81M $2.14M +$2.14M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 $5.68M $2.14M +$2.14M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 $3.54M $2.14M +$2.14M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 $1.4M $1.4M Oct 1, 2016 Dec 31, 2016 10-K 2019-02-28
Q3 2016 $0 Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-08
Q2 2016 $0 Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 $0 Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.